24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Varvara Solodovnikova, Ilhomjon Butabekov, Bern-Thomas Nyang’wa, Katherine Fielding et al.
Citations
5 citations
Journal
The Lancet Global Health
Topics
Tuberculosis Research and Epidemiology
Field-Weighted Citation Impact (FWCI)
6.98
article
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Varvara Solodovnikova, Ilhomjon Butabekov, Bern-Thomas Nyang’wa, Katherine Fielding, Maninder Pal Singh, Mohammed Rassool, Pascal Jolivet, Zinaida Tigay, Sedona Sweeney, Nargiza Parpieva, Yoko V. Laurence, Catherine Berry, Tleubergen Abdrasuliev, Nazgul Samieva, Soe Moe, Emil Kazounis, Ruzilya Usmanova, Irina Liverko, Matthew Dodd, George Nyangweso, Ronelle Moodliar, Ilaria Motta, Pei Sun Aw
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Global HealthVol. 13(2)
Institutions
London School of Hygiene & Tropical Medicine (GB), Kenya AIDS Vaccine Initiative (KE), Republican Scientific and Practical Centre of Pulmonology and Tuberculosis (BY), Médecins Sans Frontières (GB), Africa Health Research Institute (ZA), International Union Against Tuberculosis and Lung Disease (US)